Vedicinals India Profile
Key Indicators
- Authorised Capital ₹ 10.00 K
- Paid Up Capital ₹ 10.00 K
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 28.72%
- Profit Growth 69.12%
- Ebitda 68.60%
- Net Worth -31.87%
- Total Assets 129.35%
About Vedicinals India
Vedicinals India Private Limited (VIPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 June 2017 (Seven years and eight months 5 days old ). Its registered office is in Pune, Maharashtra.
The Corporate was formerly known as Iges Efficiency Solutions India Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 K and a paid-up capital of Rs 10.00 K , as per Ministry of Corporate Affairs (MCA) records.
Prakash Salunke and Vaishali Salunke serve as directors at the Company.
Company Details
-
LocationPune, Maharashtra
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24100PN2017PTC170824
-
Company No.
170824
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Jun 2017
-
Date of AGM
20 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Vedicinals India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prakash Salunke
|
Director | 05-Jun-2017 | Current |
|
Vaishali Salunke
|
Director | 05-Jun-2017 | Current |
Financial Performance of Vedicinals India.
Vedicinals India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 28.72% increase. The company also saw a substantial improvement in profitability, with a 69.12% increase in profit. The company's net worth observed a substantial decline by a decrease of 31.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vedicinals India?
Unlock access to Vedicinals India's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vedicinals India?
Unlock and access historical data on people associated with Vedicinals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vedicinals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vedicinals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.